Ana Oaknin

Research interests

Publications

• ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2023.11.015

• Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

  The Lancet · 2024 · https://doi.org/10.1016/s0140-6736(24)00317-9

• Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2313811

• Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.07.011

• Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.23.02005

• ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

  International Journal of Gynecological Cancer · 2023 · https://doi.org/10.1136/ijgc-2023-004429

• European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.11.013

• Endometrial cancer

  Nature Reviews Disease Primers · 2021 · https://doi.org/10.1038/s41572-021-00324-8

• A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

  Radiology · 2021 · https://doi.org/10.1148/radiol.2021200928

• Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz135

• A decade of clinical development of PARP inhibitors in perspective

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz192

• Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-19-2226

• Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.00739

• BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-0715

• RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy099

• Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy001

• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32440-6

• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32440-6

• Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

  Gynecologic Oncology · 2017 · https://doi.org/10.1016/j.ygyno.2017.08.022

• Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30559-9

• Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2013.51.4489

• Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70244-x

Current projects

No projects listed.